Apollomics Inc. Updates Operations, Focuses on Oncology Pipeline

TL;DR

Apollomics Inc. is pushing forward with its oncology drug pipeline, with 6 candidates in clinical trials.

AI Summary

Apollomics Inc. provided an operational continuity update on October 14, 2025. The clinical-stage biotechnology company is focused on advancing innovative oncology therapies and has a pipeline of nine product candidates, with six currently in clinical development.

Why It Matters

This update signals ongoing development and strategic focus for Apollomics Inc. in the competitive oncology therapeutic space.

Risk Assessment

Risk Level: low — The filing is a routine operational update and does not contain significant financial or strategic changes that would immediately impact risk.

Key Numbers

• 9 — Product Candidates (Represents the breadth of Apollomics Inc.'s pipeline in oncology therapies.)
• 6 — Clinical Development Programs (Indicates the number of Apollomics Inc.'s product candidates currently undergoing clinical trials.)

Key Players & Entities

• Apollomics Inc. (company) — Registrant and subject of the filing

FAQ

Key Financial Figures

• $4.1 million — ounced on Form 6-K that it had received $4.1 million PIPE investments from certain investors

Filing Documents

• d71728d6k.htm (6-K) — 22KB
• d71728dex991.htm (EX-99.1) — 14KB
• g71728dsp001a.jpg (GRAPHIC) — 6KB
• g71728dsp001b.jpg (GRAPHIC) — 5KB
• 0001193125-25-238927.txt ( ) — 51KB

From the Filing

6-K OMB APPROVAL OMB Number: 3235-0116 Expires: December 31, 2026 Estimated average burden hours per response 8.7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2025. Commission File Number 001-41670 Apollomics Inc. (Translation of registrant's name into English) 989 E. Hillsdale Blvd., Suite 220, Foster City, California 94404 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-FForm 40-F Company Operational Continuity Update Apollomics Inc. (the "Company" or "Apollomics") is a clinical-stage biotechnology company advancing innovative oncology therapies to transform the treatment landscape for patients with few or no options. With a pipeline of nine product candidates across 11 programs, including six in clinical development, the Company is focused on tackling some of the most challenging cancers, such as lung cancer, brain cancer, and other solid tumors. Apollomics' strategic approach combines targeted therapies, immuno-oncology, and novel mechanisms of action designed to overcome resistance and deliver meaningful clinical outcomes. The Company is currently conducting a global Phase 2 trial of APL-101 (vebreltinib), a promising targeted therapy that has seen positive results from clinical trials involving over 280 patients. With its late-stage clinical trial status and its history of positive patient developments, APL-101 represents a core investment of Apollomics that must be continued and further developed. On August 28, 2025, the Company, citing financial concerns, announced on Form 6-K (the "August 28 Announcement") that it "expected" to discontinue all clinical trial activities related to APL-101 (vebreltinib) (also known as SPARTA) and that it intended to seek shareholder approval to wind up the Company's business. On September 3, 2025 (the "September 3 Funding"), the Company announced on Form 6-K that it had received $4.1 million PIPE investments from certain investors and appointed a new board of directors (the "Current Board"). The Current Board subsequently appointed a new management team, led by Hung-wen (Howard) Chen ("Howard Chen"), as Chief Executive Officer, and Yi-kuei (Alex) Chen ("Alex Chen"), as Chief Operating Officer, and Peter Lin, as Chief Financial Officer. With additional funding and new leadership, the Company has reversed its wind-up plans. Apollomics is continuing pre-existing operations and advancing the global development and commercialization of its intellectual property assets, such as APL-101 (vebreltinib). Although the former Board and management of Apollomics had announced that they "expect[ed]" to discontinue the SPARTA clinical trials associated with APL-101, there has been no stoppage, and under its current management, Apollomics aims to complete the clinical trials. Promptly after the September 3 Funding, the Company's new management team began notifying its clinical research organizations ("CROs") and licensing partners (including its CRO associated with the SPARTA trials of vebreltinib (Sofpromed Investigación Clínica, S.L.), its CRO and licensing partner in China (Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd), and its licensing partner in Taiwan (LaunXP Biomedical Co., Ltd.)) about the leadership transition and continuity of operations and clinical trials. All contracts with the Company's current CROs are fully paid and up to date. The Company has developed a comprehensive business plan for the next 12 months to ensure continued operations and strengthen its clinical development programs. Apollomics remains committed to the ongoing global multi-country, multi-center SPARTA clinical trial of APL-101 (vebreltinib). This program is important for maximizing the therapeutic potential of vebreltinib across multiple tumor types and to support regulatory submissions in the U.S., EU, and other major markets. In addition, the Company intends to leverage Chinese APL-101 (vebreltinib) approvals for MET-amplified NSCLC and GBM, obtained via its CRO and licensing partner in China, to pursue regulatory submissions in Southeast Asia, the Middle East, and other potential emerging markets outside of China. Apollomics currently has 12 full time employees. Apollomics expects total headcount to reach 15 by October 31, 2025. Apollomics believes that the currently planned headcount is sufficient to maintain clinical trials and operations. Apollomics also intends to reduce headcount in China and re-allocate headcount to the U.S. and Taiwan. The information contained in this Form 6-K relating to the changes in management and the Company's current operations is incorporated by reference into the Company's registration statem

View Full Filing

View this 6-K filing on SEC EDGAR